Kian-Chung Ong, FRCP (Edin); Arul Earnest, MSc; and Suat-Jin Lu, MBBS

Size: px
Start display at page:

Download "Kian-Chung Ong, FRCP (Edin); Arul Earnest, MSc; and Suat-Jin Lu, MBBS"

Transcription

1 A Multidimensional Grading System (BODE Index) as Predictor of Hospitalization for COPD* Kian-Chung Ong, FRCP (Edin); Arul Earnest, MSc; and Suat-Jin Lu, MBBS Study objectives: We hypothesized that the BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) index would better predict hospitalization for COPD than FEV 1 alone, and the purpose of this study was to test this hypothesis in a cohort of patients with COPD. Design: Historical cohort study. Setting: University-affiliated hospital. Patients: One hundred twenty-seven patients with COPD recruited from the outpatient clinic of a single institution were followed up for a mean period of 16.2 months. Measurements: The BODE index was calculated for each patient using variables obtained within 4 weeks of enrollment. The main outcome measure was the number of hospital admissions for COPD during follow-up. We used the Poisson regression model to quantify and compare the relationship between FEV 1 and BODE scores with the number of hospital admissions. Results: During the follow-up period, 47% of patients required at least one hospital admission and 17% died. Using Poisson regression analysis, a significant effect of BODE score on the number of hospital admissions was found (incidence rate ratio, 1.20; 95% confidence interval [CI], 1.15 to 1.25; p < 0.001). In comparison, there was a significant but smaller effect of the FEV 1 percentage of predicted on the number of hospital admissions (incidence rate ratio, 0.08; 95% CI, 0.04 to 0.16; p < 0.001). When categorizing the BODE scores into four quartiles, we found that the BODE index is also a better predictor of hospital admissions than the staging system of COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease. The pseudo r 2 using quartiles of the BODE index as the predictor was 0.16, as compared to 0.04 for stages of severity based on FEV 1. Conclusions: The BODE staging system, which includes in addition to FEV 1 other physiologic and clinical variables, helps to better predict hospitalization for COPD. (CHEST 2005; 128: ) Key words: airflow; body mass index; dyspnea; exercise capacity; obstruction; prognosis; risk factors Abbreviations: ATS American Thoracic Society; BODE body mass index, airflow obstruction, dyspnea, and exercise capacity; CI confidence interval; GOLD Global Initiative for Chronic Obstructive Lung Disease; HR hazard ratio; HSDP Health Service Development Program; IRR incidence rate ratio; MRC Medical Research Council *From the Department of Respiratory Medicine (Dr. Ong and Mr. Earnest) and Clinical Research Unit (Dr. Lu), Tan Tock Seng Hospital, Singapore, Tan Tock Seng Hospital, Singapore. Manuscript received March 28, 2005; revision accepted June 1, Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( org/misc/reprints.shtml). Correspondence to: Kian-Chung Ong, FRCP (Edin), Department of Respiratory Medicine, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore ; kian_chung_ong@ttsh. com.sg COPD is a slowly progressive disorder characterized by airflow obstruction that is not fully reversible. 1 Although the progression of COPD is usually gradual, the disease is often associated with exacerbations of respiratory symptoms. Such exacerbations of symptoms requiring medical intervention are important clinical events in COPD, and they place a heavy burden on health-care resources. In many countries, exacerbations of COPD are a leading cause of hospital admissions among men, and expenditures for hospitalizations represent the bulk of all COPD-related medical-care costs. 2 The association between potential risk factors and hospitalization for exacerbation of COPD has been assessed. A large number of potentially modifiable risk factors of COPD exacerbation could be found among a large group of patients hospitalized for COPD. 3 In a case-control study 4 of a wide range of potential risk factors, lower FEV 1 was one of several factors found to be independently associated with a 3810 Clinical Investigations

2 higher risk of admission for a COPD exacerbation. In a subsequent prospective study, 5 after adjusting for sociodemographic and clinical factors, physical activity was identified to show a strong association with reduced risk of COPD readmission. These studies suggest that factors other than the degree of airflow obstruction may influence the frequency of hospitalization for COPD, and a multidimensional grading system that assesses the respiratory and systemic manifestations of COPD would thus categorize and predict this outcome better than a classification of disease severity based on FEV 1 alone. Recently, the BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) index, a multidimensional grading system, was shown to be better than FEV 1 in predicting the risk of death among patients with COPD. 6 This multistage scoring system that incorporates an assessment of symptoms, nutritional state, and exercise capacity together with the spirometric measure of airflow (FEV 1 ) can provide useful prognostic information in patients with COPD. Although the BODE index has been shown to be a predictor of the risk of death, it is not known whether this index is a useful indicator of the degree of utilization of health-care resources. We hypothesized that the BODE index would better predict hospitalization for COPD than FEV 1 alone, and the purpose of this study is to test this hypothesis in a cohort of patients with hospitalization for COPD as the primary outcome variable. Patient Recruitment Materials and Methods Between October 2002 and April 2004, patients with a wide range of severity of COPD, regardless of whether they had previous COPD hospital admissions or not, were recruited from a single institution and enrolled in the Health Service Development Program (HSDP) for COPD funded by the Ministry of Health, Singapore. This pilot service project provided several interventions optimal medication, patient education, home care, and telephone support and is aimed at reducing hospitalization for COPD. The main outcome measure monitored in this project was the frequency of hospital admissions for COPD. Patients were recruited from the outpatient clinic. A diagnosis of COPD was established by a pulmonologist based on medical history, current symptoms, and available pulmonary function tests following Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. 1 An exacerbation was defined as an increase in dyspnea, sputum production, or sputum purulence. 7 At enrollment, all patients were in clinically stable condition and receiving appropriate therapy. The exclusion criteria were an illness other than COPD that was likely to result in death within 2 years; bronchial asthma, defined as an increase in the FEV 1 15% above the baseline value or 200 ml after the administration of a bronchodilator; an inability to perform the lung function and 6-min walk tests; myocardial infarction within the preceding 4 months; unstable angina; or congestive heart failure (New York Heart Association class III or IV). The BODE index was calculated for each patient using variables obtained within 4 weeks of enrollment. For calculation of the BODE index, we used the empirical model as previously described 6 : for each threshold value of FEV 1, distance walked in 6 min, and score on the modified Medical Research Council (MRC) dyspnea scale, 8 the patients received points ranging from 0 (lowest value) to 3 (maximal value). For body mass index the values were 0 or 1. The points for each variable were added, so that the BODE index ranged from 0 to 10 points in each patient. The postbronchodilator FEV 1 as a percentage of the predicted value 9 was used and classified according to the three stages identified by the American Thoracic Society (ATS). 10 The best of two 6-min walk tests performed at least 30-min apart 11 was used for scoring. This study involved the retrospective analysis of baseline variables on entry as well as outcomes during follow-up in the HSDP project for COPD. The study protocol was approved by the institutional ethics committee. Follow-up Information on admissions and readmissions during the follow-up period was obtained from the hospital database as well as the Electronic Medical Records Exchange, a national administrative database that monitors and records admissions to all major public hospitals in Singapore. All admissions with a main and/or secondary diagnosis fulfilling any of the following code combinations (according to the International Classification of Diseases, Ninth Revision) were recorded as hospital admissions for COPD: (1) (COPD group), (pneumonia), 487 (influenza), or (respiratory failure) as the main diagnosis; (2) 428 (cardiac failure) as the main diagnosis if (respiratory failure) or (acute exacerbation of chronic bronchitis) were the secondary diagnosis; and (3) any other respiratory problems [011 (tuberculosis), 466 (acute bronchitis), (pneumoconiosis), (deficit 1 -antitrypsin)] as the main diagnosis if or were the secondary diagnosis. Criteria of the expert consensus of the ATS were used to define such combinations. 5,10 At enrollment, a respiratory nurse gave all patients brief education about their disease and treatment. They were also encouraged to call the HSDP office if they were in need of assistance for a worsening of respiratory symptoms, and they would normally have called their general practitioner or specialist or have come to the emergency department instead. At the HSDP office, case managers answered all telephone calls and, in consultation with a pulmonologist, offered treatment advice by telephone or invited the patient to come to the hospital for consultation. When deemed necessary, a respiratory nurse conducted home visits to assess their condition. Pharmacologic treatment of exacerbations was not standardized. Other than these services, patients received usual care from their pulmonologist or internal medicine specialist during follow-up. Patients were seen at least once every 3 months during the follow-up period or until death. The patient and family were contacted if the patient failed to return for appointments. There were no losses to follow-up, as all patients were contacted for telephone interview, registered as dead in the mortality registry, visited in the outpatient clinics, or hospitalized during the follow-up period. Death from any cause and from specific respiratory causes was recorded. The cause of death was determined after reviewing the medical record and death certificate. Statistical Analysis The main outcome measure was the number of hospital admissions for COPD (according to the above code combinawww.chestjournal.org CHEST / 128 / 6/ DECEMBER,

3 tions) during follow-up. We used the Poisson regression model 12 to quantify and compare the relationship between FEV 1 and BODE scores with the number of hospital admissions. To correct for the difference in the follow-up period between patients, we adjusted for this in the Poisson model. The incidence rate ratios (IRRs) and the corresponding 95% confidence intervals (CIs) are presented as a measure of the effect size. Furthermore, we also used the Kruskal-Wallis test to compare the geometric mean rate of hospitalization between groups with higher and lower BODE index scores. Geometric means of the rate of hospitalization were used so that patients with no hospital admissions were excluded from analysis. In addition to the primary outcome, we also studied the effect of the two measures on mortality. For this purpose, we used the Cox regression model. 13 Survival time was defined as the interval between date of enrollment and date of final follow-up (October 30, 2004) or the date of death instead for those who died while during follow-up. The hazard ratios (HRs) and their corresponding 95% CIs are presented as a measure of the effect size. The Mann-Whitney U test was used to compare the median BODE scores between those who died and those who survived. Data analysis was performed using statistical software (Stata V7.0; StataCorp; College Station, TX), and all tests were done at the 5% level of significance. Results One hundred twenty-seven patients were followed up. The baseline characteristics of these patients are shown in Table 1. The mean age SD was years, and mean FEV 1 was 43.7% of predicted. The number of patients in stages I to IV of COPD severity as defined by GOLD and the median BODE scores of the patients in each category are shown in Table 2. The vast majority of patients had moderate-to-very severe COPD (stages II to IV). The median BODE scores were progressively higher from stage I to stage IV. Table 3 shows the classification of patients according to BODE index score and individual variable scores. Patients in the cohort generally fared worse in airflow obstruction score Table 1 Baseline Characteristics of Patients in the Cohort (n 127)* Characteristics Data Male/female gender, No. 116/11 Age, yr Body mass index, kg/m FEV 1,L FEV 1, % predicted FVC, L Modified MRC dyspnea scale Six-minute walk distance, m BODE index score *Values are presented as mean SD unless otherwise indicated. Scores on the modified MRC dyspnea scale can range from 0 to 4, with a score of 4 indicating that the patient is too breathless to leave the house or becomes breathless when dressing or undressing. Table 2 Classification of Patients in the Cohort According to Airflow Obstruction With the Median BODE Index Scores in Each Category (n 127) Severity of COPD* Patients, No. BODE Index Median Range Stage I (FEV 1 80 % predicted) Stage II (50% FEV 1 80% predicted) Stage III (30% FEV 1 50% predicted) Stage IV (FEV 1 30% predicted or FEV 1 50% predicted plus chronic respiratory failure ) *Stage I to IV of COPD were defined by the GOLD. 1 Respiratory failure: Pao 2 60 mm Hg with or without Paco 2 50 mm Hg while breathing air at sea level. than dyspnea and exercise capacity scores. Ten percent of patients had at least one significant comorbid condition. The mean duration of follow-up in the cohort was months (range, 6 to 24 months). There Table 3 Classification of Patients in the Cohort According to BODE Index Score and Individual Variable Scores (n 127) Characteristics Patients, No. (%) BODE index score 0 4 (3) 1 17 (13) 2 13 (10) 3 20 (16) 4 14 (11) 5 14 (11) 6 13 (10) 7 11 (9) 8 10 (8) 9 7 (6) 10 4 (3) Body mass index score 0 60 (47) 1 67 (53) Airflow obstruction score 0 21 (16) 1 20 (16) 2 35 (28) 3 51 (40) Dyspnea score 0 54 (43) 1 36 (28) 2 20 (16) 3 17 (13) Exercise capacity score 0 58 (46) 1 21 (16) 2 35 (28) 3 13 (10) 3812 Clinical Investigations

4 were 60 patients (47%) who required at least one hospital admission for COPD during the follow-up period. The mean number of admissions for COPD was during follow-up. The mean duration of hospital stay per admission was days. Patients with higher BODE scores had higher rates of hospitalization. The geometric mean number of hospitalizations per month for patients with BODE scores ranging from 0 to 5 was 0.32, and the corresponding number for patients with BODE scores ranging from 6 to 10 was 0.42 (p 0.001). Using Poisson regression analysis, a significant effect of BODE score on the number of hospital admissions (IRR, 1.20; 95% CI, 1.15 to 1.25; p 0.001) was found (Table 4). In comparison, there was also a significant but smaller effect of the FEV 1 percentage of predicted on the number of hospital admissions (IRR, 0.08; 95% CI, 0.04 to 0.16; p 0.001). All the individual components of the BODE index are significantly associated with hospitalization (Table 4). When categorizing the BODE scores into four quartiles 6 (quartile 1, score of 0 to 2; quartile 2, score of 3 to 4; quartile 3, score of 5 to 6; and quartile 4, a score of 7 to 10), we found that the BODE index is also a better predictor of hospital admissions than the staging system of COPD as defined by GOLD (Table 5). The pseudo r 2 using quartiles of the BODE index as the predictor was 0.16, as compared to 0.04 for stages of severity based on FEV 1. The IRR is essentially the ratio of the rates of hospitalization of two groups. When comparing patients with BODE scores of 3 or 4 vs those with scores of 0 to 2 in Table 5, the ratio of the incidence rates between the two groups was 1.94, ie, the latter group was about twice as likely to be admitted to hospital. It is unclear why patients with BODE scores of 5 or 6 were less likely to require hospitalization than those with BODE scores of 0 to 2. Perhaps differences in patient characteristics or other unmeasured confounders have contributed to this finding. It could also be that, as the patients with BODE scores 5 or 6 were at higher risk of death than patients of any other BODE quartile (Table 6 and described below), their hospitalization rates were lower than patients of other BODE quartiles. There were 22 deaths (17%), and all of the deaths were due to respiratory insufficiency. The median BODE score was lower among survivors than among those who died (4 vs 6, respectively; p 0.003). There was a significant effect of BODE score on mortality (HR, 1.30; 95% CI, 1.08 to 1.56; p 0.006), but no significant effect of the FEV 1 percentage of predicted on mortality was observed (Table 4). Among the individual components of the BODE index, only dyspnea score and exercise capacity are associated with mortality. The HR of mortality for the patients with BODE scores of 5 to 6 was 9.41 (95% CI, 1.16 to 76.49; p 0.036) as compared to those with BODE scores of 0 to 2 (Table 6). As the HR models the time until death, the patients with BODE scores of 5 or 6 would be approximately nine times more likely to die during follow-up compared to those with BODE scores of 0 to 2. Similarly, the HR of mortality for those with BODE scores of 7 to 10 was also higher than in patients with BODE scores of 0 to 2, although this difference only tended toward statistical significance (p 0.062). In comparison, none of the FEV 1 categories was significantly associated with mortality (Table 6). Discussion The main finding of this study is that the BODE staging system, 6 which includes in addition to FEV 1 Table 4 Predicting Hospital Admissions and Mortality Using the BODE Index Score, Individual Variable Scores, and FEV 1 Variables IRR for Hospital Admissions HR for Mortality 95% CI z Value p Value Risk of hospitalization BODE index Body mass index score Airflow obstruction score Dyspnea score Exercise capacity score FEV 1 % predicted Risk of death from all causes BODE index Body mass index score Airflow obstruction score Dyspnea score Exercise capacity score FEV 1 % predicted CHEST / 128 / 6/ DECEMBER,

5 Table 5 Predicting Hospital Admissions Using Quartiles of the BODE Index and the Four Stages of COPD Severity Covariates IRR for Hospital Admissions 95% CI z Value p Value Pseudo r 2 BODE index COPD severity* Stage I 1 Stage II Stage III Stage IV *Defined by GOLD. 1 other physiologic and clinical variables, helps to better predict hospitalization in patients with COPD. COPD is a complex multidimensional disease, and classification schemes that incorporate more parameters than the degree of airflow obstruction are likely to predict outcomes more accurately. 14 FEV 1 is known to correlate poorly with symptoms, 15 quality of life, 16 exacerbation frequency, 17 and exercise intolerance. 18 Hence, newer approaches to disease assessment are required and may even supercede the current FEV 1 -based system of classification of disease severity. 19 The multistage scoring system used in this study incorporates variables that can be easily evaluated in any office setting, and the BODE index has potential widespread applicability, just like the FEV 1. Important to the acceptance for use of this new classification system is the evidence to support that it provides more useful prognostic information than FEV 1 alone. The multidimensional staging system of the BODE index has already been shown to be a superior predictor of the risk of death in COPD patients compared to the FEV 1 -based staging system by the ATS. 6 In this study, we were able to replicate the finding of the BODE index being a better predictor of mortality than the FEV 1 and, furthermore, a staging system utilizing the BODE index was Table 6 Predicting Mortality Using Quartiles of the BODE Index and the Four Stages of COPD Severity Covariates HR for Mortality 95% CI z Value p Value BODE index COPD severity* Stage I 1 Stage II Stage III Stage IV *Defined by GOLD. 1 found to have superior predictive power for this outcome compared to the GOLD classification 1 of disease severity. The latter classification of severity was based, in part, on previous recommendations of both the ATS and European Respiratory Society using spirometry as a pragmatic surrogate for disease severity. In its current form, the GOLD classification identifies five stages of COPD, although stage 0, the presence of symptoms without airflow limitation, was conceived of as an opportunity for early identification of the disease rather than a precursor of illness in all cases. The other major difference between GOLD and previous classification schemes is that individuals with respiratory failure or cor pulmonale are assigned to stage 4 irrespective of their FEV 1.It is possible that the GOLD classification may have different prognostic value compared to previous classifications of severity, even though the cut points chosen by GOLD may not have been clinically validated. At present, the criteria directed by GOLD have now been adopted by both national and international guidelines for stratifying disease severity. 20 Hence, it is important that we attempt to compare the predictive value of new approaches to disease assessment with these currently established and widely used criteria. To our knowledge, this is the first study to show that the BODE staging system better predicts hospitalization for COPD than the current COPD classification based on FEV 1. Whether FEV 1 can predict hospitalization for COPD is debatable; FEV 1 was found to be a predictor of COPD hospital admissions in two studies, 4,21 whereas others did not find this association. A multiple component staging system combining FEV 1, 6-min walking distance, dyspnea scored with the MRC scale, and Pao 2 was reported to better describe health-care resources utilization among COPD patients in different geographic areas when compared to international COPD classifications (ATS, British Thoracic Society, and GOLD). 25 The BODE index was also reported 3814 Clinical Investigations

6 to be a much better predictor of the severity in COPD acute exacerbations than FEV Additionally, the BODE index is also responsive to changes resulting from exacerbations and may capture the impact of exacerbations in patients with COPD. 27 Our findings of the usefulness of the BODE index in predicting hospitalization for COPD are also supported by the findings of a prospective study 5 of risk factors of hospital readmissions for COPD exacerbation. In that study, a strong association between usual physical activity and reduced risk of COPD readmission was demonstrated. Patients with COPD who reported an activity equivalent to walking 60 min/d had a reduction in risk of readmission to hospital of almost 50%. 5 Moreover, the association did not change when adjusted for FEV 1 or nutritional status. These results are in agreement with the increased risk of COPD hospital admission associated with a limited 6-min walking test reported by another group of investigators. 23 Therefore, it may be speculated that the superior value of the BODE index compared to FEV 1 in predicting hospital admissions for COPD that we have observed is accounted for by the evaluation of physical performance status among the individual components of the BODE scoring system. Admission to the hospital and heavy use of healthcare resources is a common feature of COPD. A clinical implication of the present study is that the BODE scoring system may prove to be helpful in health-care resource allocation and in guiding therapy for individual patients in the future. This multistage scoring system, which incorporates variables that can be evaluated easily in any office setting, should not be difficult or costly to implement routinely. As the BODE index can provide useful prognostic information of survival and hospitalization, the findings of the present study are in support of the utility of the BODE index as an assessment tool for COPD patients. 14 Limitations of this study that the authors would like to acknowledge are that a relatively small number of patients were evaluated and that the number of patients required to detect a significant difference in the predictive power of the BODE index and FEV 1 were not been prospectively determined. Nonetheless, we managed to detect significant differences between the predictors of hospitalization and mortality despite these limitations. In addition, we acknowledge that large differences in health-care resource utilization may exist in different countries and cultures. Hence, not all the findings of this study performed in a single institution may be generalized to other countries or health-care systems. Preliminary results of the health service program in which the patients in this study participated showed a significant reduction in hospital admissions and total hospitalization days. 28 Although this program conducted in our institution may have affected the overall hospitalization rates of these patients, it is unlikely to affect the conclusions of the present study, as the interventions and follow-up provided in addition to usual patient care in the program are irrespective of the baseline status of patients. In summary the BODE scoring system is a better predictor of hospitalization for COPD than the GOLD staging criteria based largely on FEV 1. These findings are in support of the use of the BODE scoring system as a practical instrument for outcomes assessment in COPD. References 1 The GOLD Expert Panel. Global strategy for the diagnosis, management and prevention of COPD. Available at: www. goldcopd.com. Accessed July 15, Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000; 117:5S 9S 3 Garcia-Aymerich J, Barreiro E, Farrero E, et al. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J 2000; 16: Garcia-Aymerich J, Monsó E, Marrades RM, et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2001; 164: Garcia-Aymerich J, Farrero E, Félez MA, et al. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003; 58: Celli BR, Cote CG, Marin JM, et al. The body mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: Mahler D, Wells C. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93: Chia SE, Wang YT, Chan OY, et al. Pulmonary function in healthy Chinese, Malay and Indian adults in Singapore. Ann Acad Med Singapore 1993; 22: American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152(Suppl):S77 S ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: McCullagh P, Nelder JA. Generalized linear models. 2nd ed. New York, NY: Chapman and Hall, 1989; Cox DR. Regression models and life-tables. J R Stat Soc 1972; 34: Rennard SI. Looking at the patient: approaching the problem of COPD. N Engl J Med 2004; 350: Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: Jones PW, Quirk FH, Baveystock CM, et al. A self-complete CHEST / 128 / 6/ DECEMBER,

7 measure of health status for chronic airflow limitation: the St. George s respiratory questionnaire. Am Rev Respir Dis 1992; 145: Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113: O Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: Calverley PMA. The GOLD classification has advanced understanding of COPD. Am J Respir Crit Care Med 2004; 170: Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ ERS position paper. Eur Respir J 2004; 23: Collet JP, Shapiro P, Ernst P, et al. Effects of an immunostimulant agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: Decramer M, Gosselink R, Troosters T, et al. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997; 10: Kessler R, Faller M, Fourgaut G, et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: Osman LM, Godden DJ, Friend JAR, et al. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997; 52: Marin JM, Alonso J, Sanchez A, et al. Value of current COPD classification versus a multiple component staging system (SCORE) as predictor of health care resource utilization [abstract]. Am J Respir Crit Care Med 2002; 165:A43 26 Marin JM, Sanchez A, Alonso JE, et al. A multivariate grading system (BODE) as predictor of the severity of exacerbation in COPD [abstract]. Am J Respir Crit Care Med 2003; 167:A23 27 Cote CG, Celli BR. Effect of exacerbations of COPD (AE) on the multidimensional body mass index (B), airflow obstruction (O), dyspnea (D) and exercise capacity (E), BODE index [abstract]. Chest 2004; 126:840S 28 Chong WF, Tan SP, Soh SC, et al. Reducing hospitalisation for acute exacerbation of chronic obstructive pulmonary disease with a home care programme. 8th Congress of the Asian Pacific Society of Respirology. Bologna, Italy: Medimond International Proceedings, 2003; Clinical Investigations

Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD?

Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD? AUTHOR COPY ORIGINAL RESEARCH Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD? Kian-Chung Ong 1 Suat-Jin Lu 1 Cindy Seok-Chin Soh 2 1 Department

More information

Bode index as a predictor of severity in patients with chronic obstructive pulmonary disease.

Bode index as a predictor of severity in patients with chronic obstructive pulmonary disease. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 5 Ver. VII (May. 2016), PP 93-100 www.iosrjournals.org Bode index as a predictor of severity

More information

exacerbation has greater impact on functional status than frequency of exacerbation episodes.

exacerbation has greater impact on functional status than frequency of exacerbation episodes. Original Article Singapore Med J 2011, 52(12) 894 Changes in the BODE index, exacerbation duration and hospitalisation in a cohort of COPD patients Bu X N, Yang T, Thompson M A, Hutchinson A F, Irving

More information

C hronic obstructive pulmonary disease (COPD) is one of

C hronic obstructive pulmonary disease (COPD) is one of 589 RESPIRATORY INFECTIONS Time course of recovery of health status following an infective exacerbation of chronic bronchitis S Spencer, P W Jones for the GLOBE Study Group... Thorax 2003;58:589 593 See

More information

A cross sectional study assessing severity and systemic involvement in chronic obstructive pulmonary disease by bode index and gold classification

A cross sectional study assessing severity and systemic involvement in chronic obstructive pulmonary disease by bode index and gold classification Original article: A cross sectional study assessing severity and systemic involvement in chronic obstructive pulmonary disease by bode index and gold classification 1Dr. Pramod Thakral, 2 Dr. Sivaranjani

More information

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH

More information

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam

More information

Health-related quality of life is associated with COPD severity: a comparison between the GOLD staging and the BODE index

Health-related quality of life is associated with COPD severity: a comparison between the GOLD staging and the BODE index Chronic Respiratory Disease 2009; 6: 75 80 http://crd.sagepub.com ORIGINAL PAPER Health-related quality of life is associated with COPD severity: a comparison between the GOLD staging and the BODE index

More information

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to: Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict

More information

JMSCR Vol 05 Issue 03 Page March 2017

JMSCR Vol 05 Issue 03 Page March 2017 www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i3.173 A Study on BODE Index as a Predictor

More information

Is there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions?

Is there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions? Respiratory Medicine (2004) 98, 178 183 Is there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions? Maria Tsoumakidou, Nikolaos Tzanakis,

More information

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH

More information

Douglas W. Mapel MD, MPH, Melissa Roberts PhD

Douglas W. Mapel MD, MPH, Melissa Roberts PhD Original Article Spirometry, the St. George s Respiratory Questionnaire, and other clinical measures as predictors of medical costs and COPD exacerbation events in a prospective cohort Douglas W. Mapel

More information

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They

More information

SGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life

SGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life SUPPLEMENTARY MATERIAL e-table 1: Outcomes studied in present analysis. Outcome Abbreviation Definition Nature of data, direction indicating adverse effect (continuous only) Clinical outcomes- subjective

More information

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary

More information

Chronic Obstructive Pulmonary Disease (COPD) Measures Document

Chronic Obstructive Pulmonary Disease (COPD) Measures Document Chronic Obstructive Pulmonary Disease (COPD) Measures Document COPD Version: 3 - covering patients discharged between 01/10/2017 and present. Programme Lead: Jo Higgins Clinical Lead: Dr Paul Albert Number

More information

Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression

Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression Eur Respir J 2005; 26: 414 419 DOI: 10.1183/09031936.05.00078504 CopyrightßERS Journals Ltd 2005 Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression G. Gudmundsson*,

More information

Course Handouts & Disclosure

Course Handouts & Disclosure COPD: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources Hospice Education Network Course Handouts & Disclosure To download presentation

More information

This is a cross-sectional analysis of the National Health and Nutrition Examination

This is a cross-sectional analysis of the National Health and Nutrition Examination SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is

More information

Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire*

Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire* Original Research COPD Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire* Makiko Meguro, Mphil; Elizabeth A. Barley, PhD, CPsychol; Sally Spencer,

More information

COPD exacerbation. Dr. med. Frank Rassouli

COPD exacerbation. Dr. med. Frank Rassouli Definition according to GOLD report: - «An acute event - characterized by a worsening of the patients respiratory symptoms - that is beyond normal day-to-day variations - and leads to a change in medication»

More information

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD) Chronic Obstructive Pulmonary Disease (COPD) Scope: The guideline provides strategies for the improved diagnosis and management of adults with chronic bronchitis and emphysema (chronic obstructive pulmonary

More information

COPD UPDATE ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center

COPD UPDATE ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center COPD UPDATE 2012 ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center Definition of COPD COPD is a preventable and treatable disease with some significant extra pulmonary effects that

More information

Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Pulmonary Disease (COPD). Chronic Obstructive Pulmonary Disease (COPD). Linde: Living healthcare 02 03 Chronic Obstructive Pulmonary Disease (COPD). A pocket guide for healthcare professionals. COPD the facts Moderate to severe

More information

Pulmonary Rehabilitation in Chronic Lung Disease; Components and Organization. Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept.

Pulmonary Rehabilitation in Chronic Lung Disease; Components and Organization. Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept. Pulmonary Rehabilitation in Chronic Lung Disease; Components and Organization Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept. Plan Chronic Respiratory Disease Definition Factors Contributing

More information

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What

More information

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease 0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find

More information

Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore $

Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore $ Respiratory Medicine (2006) 100, 2190 2196 Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore $ Kang-Hoe

More information

Is there any evidence that multi disciplinary pulmonary rehabilitation impacts on quality of life?

Is there any evidence that multi disciplinary pulmonary rehabilitation impacts on quality of life? Is there any evidence that multi disciplinary pulmonary rehabilitation impacts on quality of life? Summary of the evidence located: According to the NICE guideline on Chronic Obstructive Pulmonary Disease

More information

AECOPD: Management and Prevention

AECOPD: Management and Prevention Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London

More information

Epidemiology of COPD Prof. David M. Mannino, M.D.

Epidemiology of COPD Prof. David M. Mannino, M.D. Epidemiology of COPD David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health College of Public Health University of Kentucky 1 Outline Definitions Severity Progression

More information

Outcomes and health-related quality of life following hospitalization for an acute exacerbation of COPD

Outcomes and health-related quality of life following hospitalization for an acute exacerbation of COPD Blackwell Science, LtdOxford, UKRESRespirology1323-77992005 Blackwell Publishing Asia Pty LtdSeptember 2005103334340Original ArticleHospitalization and COPDQ Wang and J Bourbeau Respirology (2005) 10,

More information

Peian Lou 1*, Yanan Zhu 2, Peipei Chen 1, Pan Zhang 1, Jiaxi Yu 1, Ning Zhang 1, Na Chen 1, Lei Zhang 1, Hongmin Wu 2 and Jing Zhao 2

Peian Lou 1*, Yanan Zhu 2, Peipei Chen 1, Pan Zhang 1, Jiaxi Yu 1, Ning Zhang 1, Na Chen 1, Lei Zhang 1, Hongmin Wu 2 and Jing Zhao 2 Lou et al. BMC Pulmonary Medicine 2012, 12:53 RESEARCH ARTICLE Open Access Prevalence and correlations with depression, anxiety, and other features in outpatients with chronic obstructive pulmonary disease

More information

Assessment of Severity and Systemic Involvement in Chronic Obstructive Pulmonary Disease by Bode Index: A Cross-Sectional Study

Assessment of Severity and Systemic Involvement in Chronic Obstructive Pulmonary Disease by Bode Index: A Cross-Sectional Study Section: Medicine original research www.ijcmr.com Assessment of Severity and Systemic Involvement in Chronic Obstructive Pulmonary Disease by Bode Index: A Cross-Sectional Study Kumar P 1, Sanjana Rai

More information

Author s Accepted Manuscript

Author s Accepted Manuscript Author s Accepted Manuscript Low levels of physical activity predict worse survival to lung transplantation and poor early postoperative outcomesphysical activity level in lung transplantation James R.

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest

More information

Mood disorders in elderly patients hospitalized for acute exacerbation of COPD

Mood disorders in elderly patients hospitalized for acute exacerbation of COPD 7;5:7 Original investigation Mood disorders in elderly patients hospitalized for acute exacerbation of COPD I. Bonfitto, G. Moniello, M. Pascucci, A. D Urso, A. Trecca, M.D. Zanasi, A. Bellomo Department

More information

UNDERSTANDING COPD MEDIA BACKGROUNDER

UNDERSTANDING COPD MEDIA BACKGROUNDER UNDERSTANDING COPD MEDIA BACKGROUNDER What is COPD? Chronic Obstructive Pulmonary Disease (COPD) also called emphysema and/or chronic obstructive bronchitis* is a preventable lung disease caused by the

More information

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved. Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights

More information

Differential diagnosis

Differential diagnosis Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between

More information

Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation

Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease

More information

Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE

Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE For numbered affiliations see end of article. Correspondence to Dr Juan P de Torres, Pulmonary Department, Clínica Universidad de Navarra, Avda Pio XII, 36, Pamplona 31200, Spain; jpdetorres@unav.es Received

More information

Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification

Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification ORIGINAL ARTICLE COPD Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification Paul W. Jones 1, Lukasz Adamek 2, Gilbert Nadeau 2 and Norbert Banik 3 Affiliations:

More information

COPD in Korea. Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum

COPD in Korea. Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum COPD in Korea Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum Mortality Rate 1970-2002, USA JAMA,2005 Global Burden of Disease: COPD WHO & World

More information

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe

More information

HQO s Episode of Care for Chronic Obstructive Pulmonary Disease

HQO s Episode of Care for Chronic Obstructive Pulmonary Disease HQO s Episode of Care for Chronic Obstructive Pulmonary Disease Dr. Chaim Bell, MD PhD FRCPC Ontario Hospital Association Webcast October 23, 2013 Objectives 1. Describe the rationale and methodology for

More information

The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia.

The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia. The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia. Rennard, Stephen I; Sin, Donald D; Tashkin, Donald P; Calverley, Peter M; Radner, Finn Published in: Annals

More information

Productivity losses in chronic obstructive pulmonary disease a population-based survey.

Productivity losses in chronic obstructive pulmonary disease a population-based survey. Online supplement to Productivity losses in chronic obstructive pulmonary disease a population-based survey. Running head: Productivity losses in COPD. Authors: Marta Erdal, Department of Thoracic Medicine,

More information

COMORBIDITIES AS AN ELEMENT OF MULTIDIMENSIONAL PROGNOSTIC ASSESSMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

COMORBIDITIES AS AN ELEMENT OF MULTIDIMENSIONAL PROGNOSTIC ASSESSMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 2008, 59, Suppl 6, 297 301 www.jpp.krakow.pl M. GRABICKI 1, H. PARYSEK 1, H. BATURA-GABRYEL 1, I. BRODNICKA 2 COMORBIDITIES AS AN ELEMENT OF MULTIDIMENSIONAL PROGNOSTIC

More information

A Comparison of the BODE Index and the GOLD Stage Classification of COPD Patients in the Evaluation of Physical Ability

A Comparison of the BODE Index and the GOLD Stage Classification of COPD Patients in the Evaluation of Physical Ability A Comparison of the BODE Index and the GOLD Stage Classification of COPD Patients in the Evaluation of Physical Ability J.Phys. Ther. Sci 23: 437-441, 2011 KUNIHIKO ANAMI MS, PT 1), JUN HORIE MS, PT 2,3),

More information

CARE OF THE ADULT COPD PATIENT

CARE OF THE ADULT COPD PATIENT CARE OF THE ADULT COPD PATIENT Target Audience: The target audience for this clinical guideline is all MultiCare providers and staff including those associated with our Clinically Integrated Network. The

More information

Acute Exacerbations of COPD in Subjects Completing Pulmonary Rehabilitation

Acute Exacerbations of COPD in Subjects Completing Pulmonary Rehabilitation Acute Exacerbations of COPD in Subjects Completing Pulmonary Rehabilitation S. Jocelyn Carr, Roger S. Goldstein and Dina Brooks Chest 2007;132;127-134; Prepublished online May 2, 2007; DOI 10.1378/chest.07-0269

More information

A Randomized Controlled Trial of Follow-up of Patients Discharged From the Hospital Following Acute Asthma*

A Randomized Controlled Trial of Follow-up of Patients Discharged From the Hospital Following Acute Asthma* Original Research ASTHMA A Randomized Controlled Trial of Follow-up of Patients Discharged From the Hospital Following Acute Asthma* Best Performed by Specialist Nurse or Doctor? James A. Nathan, MRCP;

More information

Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center

Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center dtaylor@ochsner.org Observations from Yesterday EPIC is epidemic No EMR No Way!!! Accountability/Benchmarking

More information

Outcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized

Outcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Page 126. Type of Publication: Original Research Paper. Corresponding Author: Dr. Rajesh V., Volume 3 Issue - 4, Page No

Page 126. Type of Publication: Original Research Paper. Corresponding Author: Dr. Rajesh V., Volume 3 Issue - 4, Page No ISSN- O: 2458-868X, ISSN P: 2458 8687 Index Copernicus Value: 49. 23 PubMed - National Library of Medicine - ID: 101731606 SJIF Impact Factor: 4.956 International Journal of Medical Science and Innovative

More information

Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study

Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study ORIGINAL ARTICLE COPD Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study Masaru Suzuki 1, Hironi Makita 1, Yoichi M. Ito 2, Katsura Nagai 1, Satoshi Konno 1 and Masaharu

More information

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation : The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease

More information

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease

More information

Self-management reduces both short- and long-term hospitalisation in COPD

Self-management reduces both short- and long-term hospitalisation in COPD Eur Respir J 2005; 26: 853 857 DOI: 10.1183/09031936.05.00093204 CopyrightßERS Journals Ltd 2005 Self-management reduces both short- and long-term hospitalisation in COPD M-A. Gadoury*, K. Schwartzman*,

More information

Validation and comparison of reference equations for the 6-min walk distance test

Validation and comparison of reference equations for the 6-min walk distance test Eur Respir J 2008; 31: 571 578 DOI: 10.1183/09031936.00104507 CopyrightßERS Journals Ltd 2008 Validation and comparison of reference equations for the 6-min walk distance test C.G. Cote, C. Casanova, J.M.

More information

Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical determinants of exacerbations in severe, early-onset COPD

Clinical determinants of exacerbations in severe, early-onset COPD Eur Respir J 2007; 30: 1124 1130 DOI: 10.1183/09031936.00009307 CopyrightßERS Journals Ltd 2007 Clinical determinants of exacerbations in severe, early-onset COPD M.G. Foreman*, D.L. DeMeo*,#, C.P. Hersh*,#,

More information

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published

More information

CLINICAL PATHWAY. Acute Medicine. Chronic Obstructive Pulmonary Disease

CLINICAL PATHWAY. Acute Medicine. Chronic Obstructive Pulmonary Disease CLINICAL PATHWAY Acute Medicine Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease Table of Contents (tap to jump to page) INTRODUCTION 1 Scope of this Pathway 1 Pathway Contacts

More information

Factors affecting survival of hospitalised patients with COPD

Factors affecting survival of hospitalised patients with COPD Eur Respir J 2005; 26: 234 241 DOI: 10.1183/09031936.05.00024804 CopyrightßERS Journals Ltd 2005 Factors affecting survival of hospitalised patients with COPD H. Gunen*, S.S. Hacievliyagil*, F. Kosar #,

More information

Title: Objective measurement of cough frequency during COPD exacerbation convalescence

Title: Objective measurement of cough frequency during COPD exacerbation convalescence The final publication is available at Springer via http://dx.doi.org/10.1007/s00408-015-9782-y Title: Objective measurement of cough frequency during COPD exacerbation convalescence Michael G Crooks 1,

More information

Commissioning for Better Outcomes in COPD

Commissioning for Better Outcomes in COPD Commissioning for Better Outcomes in COPD Dr Matt Kearney Primary Care & Public Health Advisor Respiratory Programme, Department of Health General Practitioner, Runcorn November 2011 What are the Commissioning

More information

POLICIES AND PROCEDURE MANUAL

POLICIES AND PROCEDURE MANUAL POLICIES AND PROCEDURE MANUAL Policy: MP230 Section: Medical Benefit Policy Subject: Outpatient Pulmonary Rehabilitation I. Policy: Outpatient Pulmonary Rehabilitation II. Purpose/Objective: To provide

More information

Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement

Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial Nicolas Roche, Kenneth R. Chapman, Claus F. Vogelmeier, Felix JF Herth, Chau Thach, Robert Fogel, Petter Olsson,

More information

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong

More information

Chronic obstructive pulmonary disease in over 16s: diagnosis and management

Chronic obstructive pulmonary disease in over 16s: diagnosis and management National Institute for Health and Care Excellence Final Chronic obstructive pulmonary disease in over 16s: diagnosis and management [D] Diagnosing COPD and predicting outcomes NICE guideline NG115 Evidence

More information

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease Thorax 1999;54:581 586 581 Academic Department of Respiratory Medicine, St Bartholomew s and Royal London School of Medicine and Dentistry, London Chest Hospital, London, UK EAPaul R Garrod R Garnham J

More information

QUALITY OF LIFE MEASURED BY THE ST GEORGE'S RESPIRATORY QUESTIONNAIRE AND SPIROMETRY

QUALITY OF LIFE MEASURED BY THE ST GEORGE'S RESPIRATORY QUESTIONNAIRE AND SPIROMETRY ERJ Express. Published on January 22, 2009 as doi: 10.1183/09031936.00116808 QUALITY OF LIFE MEASURED BY THE ST GEORGE'S RESPIRATORY QUESTIONNAIRE AND SPIROMETRY 1 Mark Weatherall, 2 Suzanne Marsh, 2 Philippa

More information

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. 1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness

More information

A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma

A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma Eur Respir J 1999; 1: 591±596 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 93-1936 A comparison of global questions versus health status questionnaires

More information

Francesco Blasi Head Respiratory Medicine Section Cardio-Thoracic Department University of Milan, Italy

Francesco Blasi Head Respiratory Medicine Section Cardio-Thoracic Department University of Milan, Italy COPD EXACERBATIONS Francesco Blasi Head Respiratory Medicine Section Cardio-Thoracic Department University of Milan, Italy COPD OUTCOMES Cazzola M et al. ERJ 2008 COPD AND CARDIOVASCULAR DISEASE Cumulative

More information

Chronic obstructive pulmonary disease in over 16s: diagnosis and management

Chronic obstructive pulmonary disease in over 16s: diagnosis and management National Institute for Health and Care Excellence Draft for consultation Chronic obstructive pulmonary disease in over 16s: diagnosis and management [D] Diagnosing COPD and predicting outcomes NICE guideline

More information

Community COPD Service Protocol

Community COPD Service Protocol Community COPD Service Protocol Acknowledgements This protocol is based on the following documents: 1. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults

More information

Paradoxical results in the study of risk factors of chronic obstructive pulmonary disease (COPD) re-admission

Paradoxical results in the study of risk factors of chronic obstructive pulmonary disease (COPD) re-admission Respiratory Medicine (2004) 98, 851 857 Paradoxical results in the study of risk factors of chronic obstructive pulmonary disease (COPD) re-admission Judith Garcia-Aymerich a, *, Ramon M Marrades b, Eduard

More information

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary and secondary

More information

COPD in primary care: reminder and update

COPD in primary care: reminder and update COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice

More information

C.S. HAWORTH 1, A. WANNER 2, J. FROEHLICH 3, T. O'NEAL 3, A. DAVIS 4, I. GONDA 3, A. O'DONNELL 5

C.S. HAWORTH 1, A. WANNER 2, J. FROEHLICH 3, T. O'NEAL 3, A. DAVIS 4, I. GONDA 3, A. O'DONNELL 5 Inhaled Liposomal Ciprofloxacin in Patients With Non-Cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa: Results From Two Parallel Phase III Trials (ORBIT-3 and -4) C.S. HAWORTH 1, A. WANNER

More information

Pharmacotherapy for COPD

Pharmacotherapy for COPD 10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in

More information

รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น

รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines

More information

They Can t Bury You while You re Still Moving: Update on Pulmonary Rehabilitation

They Can t Bury You while You re Still Moving: Update on Pulmonary Rehabilitation They Can t Bury You while You re Still Moving: Update on Pulmonary Rehabilitation Richard ZuWallack, MD Associate Chief, Pulmonary and Critical Care St. Francis Hospital, Hartford, CT Professor of Medicine

More information

9/22/2015 CONFLICT OF INTEREST OBJECTIVES. Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR

9/22/2015 CONFLICT OF INTEREST OBJECTIVES. Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org scerreta@copdfoundation.org CONFLICT OF INTEREST

More information

Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR

Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org scerreta@copdfoundation.org CONFLICT OF INTEREST

More information

Patient characteristics Intervention Comparison Length of followup

Patient characteristics Intervention Comparison Length of followup ORAL MUCOLYTICS Ref ID: 2511 Bachh AA, Shah NN, Bhargava R et al. Effect oral N- in COPD - A randomised controlled trial. JK Practitioner. 2007; 14(1):12-16. Ref ID: 2511 RCT Single blind; unclear allocation

More information

FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery

FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2010 FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery Nicholas L Mills, David A McAllister, Sarah Wild, John D MacLay,

More information

Juan P. de Torres, MD; Ciro Casanova, MD; Concepción Hernández, MD; Juan Abreu, MD; Armando Aguirre-Jaime, ScM; and Bartolome R.

Juan P. de Torres, MD; Ciro Casanova, MD; Concepción Hernández, MD; Juan Abreu, MD; Armando Aguirre-Jaime, ScM; and Bartolome R. Gender and COPD in Patients Attending a Pulmonary Clinic* Juan P. de Torres, MD; Ciro Casanova, MD; Concepción Hernández, MD; Juan Abreu, MD; Armando Aguirre-Jaime, ScM; and Bartolome R. Celli, MD Objectives:

More information

MULTICARE Health System Care of the Adult Chronic Obstructive Pulmonary Disease (COPD) Patient

MULTICARE Health System Care of the Adult Chronic Obstructive Pulmonary Disease (COPD) Patient Clinical Guideline Ver. 2.0 MULTICARE Health System Care of the Adult Chronic Obstructive Pulmonary Disease (COPD) Patient Target Audience: The target audience for this clinical guideline is all MHS providers

More information

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause

More information

COPD Bronchiectasis Overlap Syndrome.

COPD Bronchiectasis Overlap Syndrome. COPD Bronchiectasis Overlap Syndrome. John R Hurst 1, J Stuart Elborn 2, and Anthony De Soyza 3 on Behalf of the BRONCH-UK Consortium (D Bilton, J Bradley, JS Brown, J Duckers, F Copeland, A Floto, J Foweraker,

More information

Research in Real Life

Research in Real Life Research in Real Life Study 1: Exploratory study - identifying the benefits of pmdi versus Diskus for delivering fluticasone/salmeterol combination therapy in patients with chronic obstructive pulmonary

More information

Management of Acute Exacerbations of COPD

Management of Acute Exacerbations of COPD MiCMRC Educational Webinar Management of Acute Exacerbations of COPD August 22, 2018 MiCMRC Educational Webinar Management of Acute Exacerbations of COPD Expert Presenter: Catherine A. Meldrum PhD RN MS

More information

Self-Management Plan for COPD

Self-Management Plan for COPD Self-Management Plan for COPD This is your personal management plan. The aim of this plan is to help you have better control of your chronic obstructive pulmonary disease (COPD). It will enable you to

More information